BiotechTube
Home/4D Molecular Therapeutics/Hugh O'Neill
HO

Hugh O'Neill

Chief Business Officer

4D Molecular Therapeutics

Therapeutic Areas

OphthalmologyPulmonology

4D Molecular Therapeutics Pipeline

DrugIndicationPhase
4D-150Wet Age-Related Macular DegenerationPhase 3
4D-710Cystic FibrosisPhase 1/2
4D-175Geographic AtrophyPreclinical

Leadership Team at 4D Molecular Therapeutics

DK
David Kirn
Chief Executive Officer
RK
Robert Kim
Chief Medical Officer
AL
Augustine Lawlor
Chief Financial Officer
PF
Peter Francis
Chief Scientific Officer, Ophthalmology
View full 4D Molecular Therapeutics profile